ArticleFrontiers in immunology2026
Shared glycosylation-related molecular mechanism and immune infiltration patterns of fetal growth restriction and preeclampsia.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Placental dysfunction and immune dysregulation are central to disorders such as fetal growth restriction (FGR) and preeclampsia (PE). Although aberrant placental glycosylation has been implicated in various pregnancy complications, the specific expression patterns of glycosylation-related genes (GRGs) associated with placental pathology and their potential role in driving immune imbalance at the maternal-fetal interface remain poorly understood. Methods: First, differentially expressed gene (DEG) identification and gene set enrichment analysis based on two GEO datasets (GSE114691 and GSE203507) revealed disease-associated pathways. Weighted gene co-expression network analysis (WGCNA) further identified glycosylation-related gene modules significantly associated with disease status. Three machine learning algorithms (LASSO, random forest, and support vector machine) were employed to screen diagnostic key genes, and a predictive nomogram was constructed. The efficacy of the diagnostic model was evaluated using receiver operating characteristic curves, calibration curves, and decision curve analysis. CIBERSORT was used to assess immune cell infiltration characteristics in the placenta and decidua of FGR, PE, and PE+FGR. Furthermore, single-cell RNA sequencing validated the expression patterns of key diagnostic genes across different trophoblast subsets, and cell-cell communication networks were analyzed using CellChat. In addition, this study validated the diagnostic efficacy of key genes in real-world samples. Result: Following batch correction and integration of two datasets, 104 samples were analyzed, including controls (n=26), PE (n=28), FGR (n=23), and PE+FGR (n=27). Glycosylation-related pathways were enriched in disease groups. Intersection of WGCNA modules with glycosylation genes yielded 97 overlapping genes, from which five core genes were identified using three machine learning algorithms. A diagnostic model based on these genes showed good predictive performance across disease groups. Immune infiltration analysis implicated multiple immune cell types in disease pathogenesis. Real-world validation of expression of B3GNT2 and ST6GAL1 differed significantly between normal and PE/FGR groups. Conclusion: Five candidate hub genes (B3GNT2, ST6GAL1, GALNT11, GCNT4, and LARGE2) were identified and a nomogram was constructed for FGR, PE, and PE+FGR diagnosis. Protein-level validation confirmed significant downregulation of B3GNT2 and ST6GAL1 in placental tissues from FGR and PE patients; mRNA-level validation of GALNT11, GCNT4, and LARGE2 is provided in independent clinical samples. These hub genes were associated with key immune cell types at both the placenta and decidua.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.